报价延迟最少15分钟:2026/09/19 07:34 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.69 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.23/0.05
|
|
企业价值
224.48M
|
| 资产负债 |
|
每股账面净值
0.89
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
52.74M
|
|
每股收益
0.79
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel. |
